Smith and Nephew study shows benefits of pressure ulcer therapy

Smith and Nephew has welcomed the findings of a new study showing the benefits offered by Collagenase Santyl Ointment in the treatment of pressure ulcers.

The paper, published in the journal Advances in Wound Care, showed how pressure ulcers treated with Collagenase Santyl Ointment can achieve faster rates of granulation and epithelisation compared to medicinal honey.

Data drawn from 787 patients showed that those who received Santyl treatment on 1,034 pressure ulcers were 38 percent more likely to achieve 100 percent granulation, as well as being 47 percent more likely to achieve epithelialisation at one year.

In addition, those treated with Santyl had significantly fewer hospital outpatient visits, fewer total selective sharp debridements and a reduced rate of pressure ulcers requiring negative-pressure wound therapy.

The findings support the use of Santyl as a first-line debridement product, both in between weekly sharp debridements and as a standalone therapy.

Dr Andy Weymann, chief medical officer at Smith and Nephew, said: "This new research, using real-world electronic health record data, demonstrates Santyl is the better choice for helping patients with pressure ulcers."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.